Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar A D, Vijay V
Diabetes Research Centre, M.V. Hospital for Diabetes, WHO Collaborating Centre for Research, Education and Training in Diabetes, Royapuram, Chennai, India.
Diabetologia. 2006 Feb;49(2):289-97. doi: 10.1007/s00125-005-0097-z. Epub 2006 Jan 4.
AIMS/HYPOTHESIS: Lifestyle modification helps in the primary prevention of diabetes in multiethnic American, Finnish and Chinese populations. In a prospective community-based study, we tested whether the progression to diabetes could be influenced by interventions in native Asian Indians with IGT who were younger, leaner and more insulin resistant than the above populations.
We randomised 531 (421 men 110 women) subjects with IGT (mean age 45.9+/-5.7 years, BMI 25.8+/-3.5 kg/m(2)) into four groups. Group 1 was the control, Group 2 was given advice on lifestyle modification (LSM), Group 3 was treated with metformin (MET) and Group 4 was given LSM plus MET. The primary outcome measure was type 2 diabetes as diagnosed using World Health Organization criteria.
The median follow-up period was 30 months, and the 3-year cumulative incidences of diabetes were 55.0%, 39.3%, 40.5% and 39.5% in Groups 1-4, respectively. The relative risk reduction was 28.5% with LSM (95% CI 20.5-37.3, p=0.018), 26.4% with MET (95% CI 19.1-35.1, p=0.029) and 28.2% with LSM + MET (95% CI 20.3-37.0, p=0.022), as compared with the control group. The number needed to treat to prevent one incident case of diabetes was 6.4 for LSM, 6.9 for MET and 6.5 for LSM + MET.
CONCLUSIONS/INTERPRETATION: Progression of IGT to diabetes is high in native Asian Indians. Both LSM and MET significantly reduced the incidence of diabetes in Asian Indians with IGT; there was no added benefit from combining them.
目的/假设:生活方式改变有助于在美国多民族、芬兰和中国人群中对糖尿病进行一级预防。在一项基于社区的前瞻性研究中,我们测试了对于比上述人群更年轻、更瘦且胰岛素抵抗更强的亚洲印度裔糖耐量受损(IGT)患者,干预措施是否会影响其糖尿病进展。
我们将531名(421名男性和110名女性)IGT患者(平均年龄45.9±5.7岁,体重指数25.8±3.5kg/m²)随机分为四组。第1组为对照组,第2组接受生活方式改变(LSM)建议,第3组接受二甲双胍(MET)治疗,第4组接受LSM加MET治疗。主要结局指标是根据世界卫生组织标准诊断的2型糖尿病。
中位随访期为30个月,第1 - 4组糖尿病的3年累积发病率分别为55.0%、39.3%、40.5%和39.5%。与对照组相比,LSM使相对风险降低28.5%(95%可信区间20.5 - 37.3,p = 0.018),MET使相对风险降低26.4%(95%可信区间19.1 - 35.1,p = 0.029),LSM + MET使相对风险降低28.2%(95%可信区间20.3 - 37.0,p = 0.022)。预防一例糖尿病所需治疗人数,LSM为6.4,MET为6.9,LSM + MET为6.5。
结论/解读:亚洲印度裔IGT患者进展为糖尿病的比例很高。LSM和MET均显著降低了亚洲印度裔IGT患者的糖尿病发病率;联合使用二者并无额外益处。